The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • Bloomcole@lemmy.world
    41·
    5 hours ago

    Indeed, the way it works is horribly effective and invades the privacy of an entire bloodline.